Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis

Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9). The comparison of inclisiran with statin versus statin alone in the ORION-10 trial demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C). Our study explored whether...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2020-09, Vol.38 (9), p.1007-1020
Hauptverfasser:	Kam, Ning, Perera, Kanila, Zomer, Ella, Liew, Danny, Ademi, Zanfina
Format:	Artikel
Sprache:	eng
Schlagworte:	Atherosclerosis Cardiovascular disease Cardiovascular diseases Cholesterol Compliance Cost analysis Disease prevention Dosage and administration Drug therapy Economic aspects Enzyme inhibitors Health Administration Health care Health Economics Health technology assessment Inhibitors Markov chains Medicine Medicine & Public Health Meta-analysis Monoclonal antibodies Original Research Article Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Statins Testing Willingness to pay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!